Trials & Filings

Allegro To Begin Phase II Ophthalmic Trials

IPT trials in patients with wet AMD and VMT

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Allegro Ophthalmics has received FDA approval to begin two Phase II clinical studies of ALG-1001, an Integrin Peptide Therapy. The trials will be conducted in patients with wet age-related macular degeneration (wet AMD) and in patients with symptomatic vitreomacular traction (VMT). These Phase II studies will be the fifth and sixth studies of ALG-1001. The company has completed two Phase I studies, monotherapy studies in each of diabetic macular edema (DME) and wet AMD. Additionally, two Phase ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters